Daiichi Sankyo, Esperion Report Swissmedic Approval For NILEMDO & NUSTENDI

Daiichi Sankyo Europe GmbH (DSKYF.PK) and Esperion Therapeutics (ESPR) announced Swissmedic approval for NILEMDO tablet and NUSTENDI tablet, for people with high low-density lipoprotein cholesterol in Switzerland. NILEMDO (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients.

Lucas Schalch, Country Manager at Daiichi Sankyo Switzerland, said: "Today's approval of NILEMDO and NUSTENDI is a pivotal milestone for patients in secondary prevention, offering them new, convenient treatment options and demonstrating another step forward in our commitment to reduce the risk of atherosclerotic cardiovascular disease."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Delta Air Lines said it sees weather-related flight cancelations as AT&T and Verizon readies for 5G roll out in and around the vicinity of major U.S. airports. Most of the other airlines also confirmed the same as the implementation of the new C-Band 5G service is expected to interfere with the working of onboard aircraft instruments. Financial services firm Morgan Stanley (MS) reported Wednesday a profit for the fourth quarter that increased 10 percent from last year, reflecting 7 percent revenue growth amidst strength in Wealth Management and Investment Management business segments. Bank of America Corp. (BAC) reported Thursday that net income applicable to common shareholders for the fourth quarter grew 30 percent to $6.77 billion from last year's $5.21 billion, with earnings per share increasing to $0.82 from $0.59 in the prior year, reflecting strong operating leverage as revenues...
Follow RTT